Welcome

ESMO 2018 Key CIT readouts across tumor types

Roche Oncology strategy update

Q&A

Daniel O’Day, CEO Roche Pharmaceuticals

IMpassion130: Tecentriq + Abraxane in 1L triple-negative breast cancer

IMpower130: Tecentriq + Abraxane in 1L non-sq NSCLC

Jakob Dupont, M.D., Global Head Breast & Gyn Cancer Franchise, Pharma Development

BF1RST: Association between bTMB and Tecentriq efficacy in 1L NSCLC ALESIA: Alecensa in 1L ALK+ NSCLC in Asian patients STARTRK2: Entrectinib in NTRK+ solid tumors GO30140: Tecentriq + Avastin in 1L HCC Alan Sandler, M.D., Global Head of Lung/Head & Neck Franchise, Pharma Development, a.i. Global Head Oncology